WISER Program, Schizophrenia Clinic, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, India.
WISER Program, Schizophrenia Clinic, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, India.
Schizophr Res. 2018 May;195:475-480. doi: 10.1016/j.schres.2017.08.047. Epub 2017 Sep 1.
Persistent auditory verbal hallucinations (AVH) that are refractory to antipsychotic medications are reported in about 20-30% of schizophrenia patients. Transcranial Direct Current Stimulation (tDCS), a non-invasive and safe neuromodulatory technique, has attracted significant interest as an add-on treatment for refractory AVH in schizophrenia. Studies examining the efficacy of tDCS for refractory AVH in schizophrenia have reported inconsistent findings. In this study, using a randomized, double-blind, sham-controlled design (RCT), we sought to examine the effect of add-on tDCS [anode corresponding to left dorsolateral prefrontal cortex and cathode to left temporo-parietal junction; 2-mA, twice-daily sessions for 5-days] to treat refractory AVH in schizophrenia patients (N=25); following this RCT phase, patients that had <30% reduction in AVH severity were offered an open-label extension (OLE) active stimulation to evaluate the effect of cross-over to verum tDCS. In the RCT phase, repeated measures ANOVA with tDCS type [verum (N=12) vs. sham (N=13)] as between subjects factor demonstrated a significant tDCS-type X time-point interaction [F=21.5, p<0.001, partial-η2=0.48] with significantly greater reduction of AVH score in verum tDCS group as compared to sham group. In the OLE phase, sham-to-verum crossed over patients (N=13) showed significantly greater reduction in AVH severity than their corresponding change during RCT phase (t=2.9; p=0.01). Together, these observations add further support to the beneficial effects of add-on tDCS to treat refractory AVH schizophrenia.
持续存在且对抗精神病药物难治的幻听(AVH)在约 20-30%的精神分裂症患者中报告。经颅直流电刺激(tDCS)作为一种非侵入性和安全的神经调节技术,作为精神分裂症难治性 AVH 的附加治疗引起了极大的兴趣。研究检查了 tDCS 治疗精神分裂症难治性 AVH 的疗效,结果发现结果不一致。在这项研究中,我们使用随机、双盲、假对照设计(RCT),旨在检查附加 tDCS [阳极对应左背外侧前额叶皮层,阴极对应左颞顶交界处;2 mA,每天两次,共 5 天]对精神分裂症患者难治性 AVH 的治疗效果(N=25);在 RCT 阶段之后,AVH 严重程度降低<30%的患者接受开放标签扩展(OLE)主动刺激,以评估交叉至真实 tDCS 的效果。在 RCT 阶段,重复测量方差分析(ANOVA),以 tDCS 类型[真实(N=12)与假(N=13)]作为组间因素,显示 tDCS 类型与时间点的显著交互作用[F=21.5,p<0.001,部分η 2=0.48],真实 tDCS 组的 AVH 评分显著降低,与假组相比。在 OLE 阶段,假至真实交叉的患者(N=13)显示 AVH 严重程度的显著降低,明显高于 RCT 阶段的变化(t=2.9;p=0.01)。总之,这些观察结果进一步支持了附加 tDCS 治疗精神分裂症难治性 AVH 的有益效果。